Trifluridine-tipiracil monotherapy (RECOURSE, 3L+ mCRC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TRIFLURIDINE-TIPIRACIL |
|---|
| ID | REG-TRIFLURIDINE-TIPIRACIL-MONO |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Notes
RECOURSE Phase III (2015): chemo-refractory mCRC, TAS-102 vs placebo, mOS 7.1 vs 5.3 mo (HR 0.68). NCCN Cat 1 monotherapy option for 3L+. Mechanism: trifluridine is a thymidine analog incorporated into DNA; tipiracil inhibits thymidine phosphorylase preventing trifluridine degradation. TS-independent — distinct from prior fluoropyrimidine exposure. SUNLIGHT combination (TAS-102 + bevacizumab) is preferred where bev accessible (mOS 10.8 vs 7.5 mo combo vs mono); this monotherapy regimen is the bev-contraindicated / bev-not-funded fallback. Myelosuppression (neutropenia + anemia) is dominant toxicity; G-CSF prophylaxis NOT routine but PRN.
Used By
Indication
IND-CRC-METASTATIC-3L-TRIFLURIDINE-TIPIRACIL-MONO- IND-CRC-METASTATIC-3L-TRIFLURIDINE-TIPIRACIL-MONO